These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 32572786)

  • 41. Towards a Next-Generation Sequencing Diagnostic Service for Tumour Genotyping: A Comparison of Panels and Platforms.
    Burghel GJ; Hurst CD; Watson CM; Chambers PA; Dickinson H; Roberts P; Knowles MA
    Biomed Res Int; 2015; 2015():478017. PubMed ID: 26351634
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Gene Panel Tumor Testing in Ovarian Cancer Patients Significantly Increases the Yield of Clinically Actionable Germline Variants beyond
    Barbosa A; Pinto P; Peixoto A; Guerra J; Pinto C; Santos C; Pinheiro M; Escudeiro C; Bartosch C; Silva J; Teixeira MR
    Cancers (Basel); 2020 Sep; 12(10):. PubMed ID: 33008098
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation and comparison of two commercially available targeted next-generation sequencing platforms to assist oncology decision making.
    Weiss GJ; Hoff BR; Whitehead RP; Sangal A; Gingrich SA; Penny RJ; Mallery DW; Morris SM; Thompson EJ; Loesch DM; Khemka V
    Onco Targets Ther; 2015; 8():959-67. PubMed ID: 25960669
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Discovery of actionable genetic alterations with targeted panel sequencing in children with relapsed or refractory solid tumors.
    Lee JW; Kim NKD; Lee SH; Cho HW; Ma Y; Ju HY; Yoo KH; Sung KW; Koo HH; Park WY
    PLoS One; 2019; 14(11):e0224227. PubMed ID: 31747416
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group.
    Eder T; Hess AK; Konschak R; Stromberger C; Jöhrens K; Fleischer V; Hummel M; Balermpas P; von der Grün J; Linge A; Lohaus F; Krause M; Baumann M; Stuschke M; Zips D; Grosu AL; Abdollahi A; Debus J; Belka C; Pigorsch S; Combs SE; Budach V; Tinhofer I;
    Eur J Cancer; 2019 Jul; 116():67-76. PubMed ID: 31173964
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Validation of a next-generation-sequencing cancer panel for use in the clinical laboratory.
    Simen BB; Yin L; Goswami CP; Davis KO; Bajaj R; Gong JZ; Peiper SC; Johnson ES; Wang ZX
    Arch Pathol Lab Med; 2015 Apr; 139(4):508-17. PubMed ID: 25356985
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Analytic validation and clinical utilization of the comprehensive genomic profiling test, GEM ExTra
    White T; Szelinger S; LoBello J; King A; Aldrich J; Garinger N; Halbert M; Richholt RF; Mastrian SD; Babb C; Ozols AA; Goodman LJ; Basu GD; Royce T
    Oncotarget; 2021 Apr; 12(8):726-739. PubMed ID: 33889297
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Correction to: Iluvien™ (Fluocinolone Acetonide 0.19 mg Intravitreal Implant) in the Treatment of Diabetic Macular Edema: A Review.
    Fusi-Rubiano W; Blow RR; Lane M; Morjaria R; Denniston AK
    Ophthalmol Ther; 2020 Mar; 9(1):205. PubMed ID: 32034688
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Next-Generation Sequencing: Targeting Targeted Therapies.
    McCutcheon JN; Giaccone G
    Clin Cancer Res; 2015 Aug; 21(16):3584-5. PubMed ID: 25847989
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Development and validation of the JAX Cancer Treatment Profile™ for detection of clinically actionable mutations in solid tumors.
    Ananda G; Mockus S; Lundquist M; Spotlow V; Simons A; Mitchell T; Stafford G; Philip V; Stearns T; Srivastava A; Barter M; Rowe L; Malcolm J; Bult C; Karuturi RK; Rasmussen K; Hinerfeld D
    Exp Mol Pathol; 2015 Feb; 98(1):106-12. PubMed ID: 25562415
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Panel-based next-generation sequencing identifies prognostic and actionable genes in childhood acute lymphoblastic leukemia and is suitable for clinical sequencing.
    Ishida H; Iguchi A; Aoe M; Takahashi T; Tamefusa K; Kanamitsu K; Fujiwara K; Washio K; Matsubara T; Tsukahara H; Sanada M; Shimada A
    Ann Hematol; 2019 Mar; 98(3):657-668. PubMed ID: 30446805
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Complexity of genome sequencing and reporting: Next generation sequencing (NGS) technologies and implementation of precision medicine in real life.
    Morganti S; Tarantino P; Ferraro E; D'Amico P; Viale G; Trapani D; Duso BA; Curigliano G
    Crit Rev Oncol Hematol; 2019 Jan; 133():171-182. PubMed ID: 30661654
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Next-generation sequencing analysis of receptor-type tyrosine kinase genes in surgically resected colon cancer: identification of gain-of-function mutations in the RET proto-oncogene.
    Mendes Oliveira D; Grillone K; Mignogna C; De Falco V; Laudanna C; Biamonte F; Locane R; Corcione F; Fabozzi M; Sacco R; Viglietto G; Malanga D; Rizzuto A
    J Exp Clin Cancer Res; 2018 Apr; 37(1):84. PubMed ID: 29665843
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Towards standardization of next-generation sequencing of FFPE samples for clinical oncology: intrinsic obstacles and possible solutions.
    Ivanov M; Laktionov K; Breder V; Chernenko P; Novikova E; Telysheva E; Musienko S; Baranova A; Mileyko V
    J Transl Med; 2017 Jan; 15(1):22. PubMed ID: 28137276
    [TBL] [Abstract][Full Text] [Related]  

  • 55. IMPACT web portal: oncology database integrating molecular profiles with actionable therapeutics.
    Hintzsche JD; Yoo M; Kim J; Amato CM; Robinson WA; Tan AC
    BMC Med Genomics; 2018 Apr; 11(Suppl 2):26. PubMed ID: 29697364
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Not All Next Generation Sequencing Diagnostics are Created Equal: Understanding the Nuances of Solid Tumor Assay Design for Somatic Mutation Detection.
    Gray PN; Dunlop CL; Elliott AM
    Cancers (Basel); 2015 Jul; 7(3):1313-32. PubMed ID: 26193321
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inter-laboratory proficiency testing scheme for tumour next-generation sequencing in Ontario: a pilot study.
    Spence T; Stickle N; Yu C; Chow H; Feilotter H; Lo B; McCready E; Sadikovic B; Siu LL; Bedard PL; Stockley TL
    Curr Oncol; 2019 Dec; 26(6):e717-e732. PubMed ID: 31896942
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Targeted next generation sequencing identified clinically actionable mutations in patients with esophageal sarcomatoid carcinoma.
    Lu H; Yang S; Zhu H; Tong X; Xie F; Qin J; Han N; Wu X; Fan Y; Shao YW; Mao W
    BMC Cancer; 2018 Mar; 18(1):251. PubMed ID: 29506494
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical sequencing using a next-generation sequencing-based multiplex gene assay in patients with advanced solid tumors.
    Kou T; Kanai M; Yamamoto Y; Kamada M; Nakatsui M; Sakuma T; Mochizuki H; Hiroshima A; Sugiyama A; Nakamura E; Miyake H; Minamiguchi S; Takaori K; Matsumoto S; Haga H; Seno H; Kosugi S; Okuno Y; Muto M
    Cancer Sci; 2017 Jul; 108(7):1440-1446. PubMed ID: 28440963
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical application of amplicon-based next-generation sequencing in cancer.
    Chang F; Li MM
    Cancer Genet; 2013 Dec; 206(12):413-9. PubMed ID: 24332266
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.